Hints and tips:
Related Topics
...LifeArc has royalty rights on other antibody drugs, including Tysabri for Elan and Biogen to treat multiple sclerosis, Actemra for Roche to treat rheumatoid arthritis and Entyvio for Takeda to treat colitis...
...dealing in and disposing of intellectual property rights and licenses for use in the pharmaceutical industry.”...
...Aston Martin needs to show the same élan,” we said....
...Now some scientists and pharmaceutical executives are asking if it is time to accept that the hypothesis is flawed....
...Mr Papa, 61, has been at Perrigo for almost 10 years, during which time he bought Elan, an Irish drugmaker, and moved the combined company’s headquarters from the US to Dublin in a contentious “inversion...
...Martoma had obtained non-public information about an experimental drug for Alzheimer’s that was being developed by listed companies Elan and Wyeth....
...She steadily ascended through the ranks of the sales and marketing department, first at Dura, and then at Elan Pharmaceuticals when it acquired the company....
...Malin is chaired by John Given, Elan’s former general counsel....
...Although management remains concentrated in Michigan, Perrigo moved its official headquarters to Dublin in 2013 after buying Elan of Ireland for $8.6bn....
...Perrigo moved to low-tax Ireland in 2013 through an $8.6bn tie-up with Elan. Andrew Ward...
...Perrigo acquired Irish biotech group Elan for $8.6bn in 2013 in a so-called tax inversion deal, enabling it to cut its tax rate by moving its domicile to Ireland....
...The takeover will further shift Perrigo’s centre of gravity from the US, 16 months after its $8.6bn acquisition of Elan of Ireland....
...Among companies that re-domiciled as Irish after “inversions” are Perrigo, which bought Elan, and Actavis, after its Warner Chilcott acquisition....
...Although Elan’s shareholders blocked all the planned purchases – not surprisingly, given their quality – they backed the buyback and Royalty’s hostile bid lapsed....
...The news on Monday that Mallinckrodt, a Dublin drugmaker, has agreed to pay $5.6bn for US rival Questcor Pharmaceuticals marks the latest in a string of healthcare deals to hit the market since January....
...In one email to a consulting firm, Mr Ross stated he “decided not to be the keynote for the Elan announcement”....
...They went back and forth over whether employees at Elan and Wyeth, co-developers of the experimental drug, had access to the data....
...It values Elan at $16.50 a share, a 10.5 per cent premium to Friday’s close and well above the maximum $15.50-a-share expired offer for Elan from Royalty Pharma....
...The stock market valued Elan on Thursday at about the same....
...Elan, the Irish pharmaceutical business facing a $6.7bn hostile bid from Royalty Pharma, said on Friday it was putting itself up for sale, in a move swiftly dismissed by the US private equity group as a...
...It has grown to become a supplier that develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products and active pharmaceutical ingredients...
...The following morning, a Monday, SAC dumped its entire $700m position in Wyeth and Elan, co-developers of the drug, and bet that their share prices would fall....
...But since Elan is no longer a pharmaceutical company in any meaningful sense of the term, it is hard to see a pure pharma group making an offer. Elan is a financial rather than a strategic buy....
...Elan shareholders.”...
...Royalty Pharma’s hostile takeover attempt for Dublin-based Elan Corp looks to be in trouble....
International Edition